Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
Trial purpose
The purpose of this study is to learn if V940 which is an individualised neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
|
national trial reference number | NCT05933577 |
|
Conditions |
Melanoma
|
|
Age Range | 18+ |
|
Sex | All |
|
Current trial phase | 3 |
|
Trial start and end dates |
07-19-2023 09-26-2030 |
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.